aBSI
- Extraprostatic lesions
- Bone Scintigraphy
aBSI provides detection and quantification of lesions for evaluation of Prostate Cancer Progression. EXINI Automated Bone Index (aBSI) marks the lesions and quantifies the disease burden.
Images shown for illustrative purposes only.
Improve inter-observer agreement with Automated BSI interpretation (k=0.96) versus qualitative visual assessment (k=0.70)1
aBSI has an independent association with overall survival (HR, 1.06; 95% CI, 1.01-1.11; P = 0.03)1
Appropriate Series
Number of frames (0028,0008) must be 1 or 2
Number of slices (0054,0081) must be 1 or 2
Pixel spacing (0028,0030) must be ≥ 1.8 mm/pixel and ≤ 2.8 mm/pixel
The anterior and posterior images may be stored as either two different series (two files with different Series Instance UID) or as one multi-frame series (one file) containing two frames.
Image pixel data should be in the 16-bit range. Images with pixels ranging from 0 to 255 (8- bit) are not sufficient.
Picture Archiving and Communications System (PACS) tool, clinical application for oncology, including lesion marking and quantitative analysis (Calculation of Bone Scan Index (BSI)).
Currently not made available with Calantic Viewer. Separately distributed by Bayer.
EU risk class and CE marking
aBSI has CE marking (CE0123) and risk class IIa.
Reimbursement status
Not reimbursed.
Contraindications
No contraindications given.
Target population
Not indicated.
Intended user
Trained healthcare professionals and researchers.
Limitations
BSI should not be reported:
- for patients with non-metastatic prostate cancer (M0),
- if image input requirements are not fulfilled,
- if atlas does not match the imaged skeleton,
- if the image(s) contains a large hotspot that includes the urinary bladder
Discover aBSI
now available as part of Calantic’s Prostate Service Line. Contact us today to learn more.
